Multiple sclerosis (MS) is a chronic, immune-mediated disorder in which the body’s defense system mistakenly attacks the central nervous system (CNS), particularly the myelin sheath, the protective covering surrounding nerve fibers. This process, known as demyelination, disrupts electrical signal transmission between the brain, spinal cord, and the rest of the body, leading to a wide range of neurological symptoms.
The exact cause of MS remains multifactorial, involving genetic susceptibility, environmental triggers, and immune dysregulation. Inflammation within the CNS leads to plaques or lesions visible on magnetic resonance imaging (MRI), which form the cornerstone of diagnosis. Clinically, patients may present with visual disturbances, limb weakness, sensory loss, ataxia, or fatigue, depending on the site of demyelination.
There are several forms of MS: relapsing-remitting, secondary progressive, and primary progressive, each with distinct clinical courses. Early diagnosis and initiation of disease-modifying therapies (DMTs) can slow progression and reduce relapse rates.
Understanding MS as an autoimmune disorder underscores the importance of immunomodulation and neuroprotection in treatment. Ongoing research into remyelination and neurorepair offers hope for more effective therapies in the future.
In essence, multiple sclerosis is the ultimate betrayal of the body by its own immune system when protection turns into destruction.
MBH/AB